左心室功能障碍与糖尿病的恶性循环:从病理生理机制到新兴治疗
本综述在PubMed检索截至2020年2月的相关文献,讨论糖尿病合并心力衰竭的流行病学、病理生理、临床表现与治疗选择。代谢与神经体液紊乱、氧化应激、炎症及微血管/大血管病变共同导致糖尿病心脏功能障碍,后者影响高达42%的心衰患者,并使心血管死亡风险增加34%。SGLT2抑制剂在降低糖尿病患者心衰结局方面显示显著效果。
要点
- 糖尿病与心衰呈双向恶性循环,预防策略和及时诊断对改善结局至关重要。
- 心衰患者中高达42%存在糖尿病这一基础疾病,糖尿病使心血管死亡风险增加34%。
- SGLT2抑制剂在降低糖尿病患者心衰结局方面显示显著效果,其获益能否扩展至射血分数保留的心衰患者、非糖尿病患者及急性期尚不明确。
核心结论
- 糖尿病与心衰通过双向且致命的恶性循环紧密相连,难以打破;预防策略和及时诊断对改善此类患者结局至关重要。
- SGLT2抑制剂是重大突破,结果高度一致;但其获益能否明确扩展至射血分数保留的心衰患者、非糖尿病患者及急性期患者仍不明确。
研究设计与样本
- 本综述为叙述性综述,通过PubMed检索截至2020年2月发表的相关文献。
- 观察性研究采用纽卡斯尔-渥太华评分评估质量,随机研究采用Cochrane协作工具评估质量。
主要发现
- 代谢与神经体液紊乱、氧化应激、炎症、微血管和大血管病变通过复杂的分子和细胞机制共同导致糖尿病心脏功能障碍。
- 糖尿病心脏功能障碍影响高达42%的心衰患者,并导致心血管死亡风险增加34%。
- 传统的指南导向心衰药物和器械治疗在糖尿病与非糖尿病患者中同样有效。
- 通过抑制钠-葡萄糖协同转运蛋白2(SGLT2)发挥作用的新型降糖药物在降低糖尿病患者心衰结局方面显示出显著效果。
- SGLT2抑制剂代表具有高度一致性发现的重大突破,但其获益能否明确扩展至射血分数保留的心衰患者、非糖尿病患者及急性期患者仍不明确。
关键数值与推荐
- 心衰患者中高达42%存在糖尿病这一基础疾病。
- 糖尿病使心血管死亡风险增加34%。
- SGLT2抑制剂在降低糖尿病患者心衰结局方面显示显著效果。
临床怎么用
- 传统指南导向的心衰药物和器械治疗在糖尿病与非糖尿病患者中同样有效,可作为基础治疗。
- SGLT2抑制剂在降低糖尿病患者心衰结局方面显示显著效果,是值得关注的治疗方向;其获益能否明确扩展至射血分数保留的心衰患者、非糖尿病患者及急性期患者仍不明确。
- 预防策略和及时诊断对改善糖尿病合并心衰患者的结局至关重要。
局限性
- SGLT2抑制剂的获益能否明确扩展至射血分数保留的心衰患者、非糖尿病患者及急性期患者仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetes and heart failure (HF) are 2 deadly and strictly related epidemic disorders. The aim of this review is to present an updated discussion of the epidemiology, pathophysiology, clinical presentation and treatment options for HF in diabetes. EVIDENCE ACQUISITION: Relevant references published up to February 2020 were identified through searches in PubMed. Quality was graded using the Newcastle-Ottawa score in observational studies and the Cochrane Collaboration tool in randomized studies. EVIDENCE SYNTHESIS: Metabolic and neurohumoral derangements, oxidative stress, inflammation, micro- and macroangiopathy all contribute through complex molecular and cellular mechanisms to cardiac dysfunction in diabetes, which in turn, results as one the most frequent underlying conditions affecting up to 42% of patients with HF and causing a 34% increased risk of cardiovascular death. On top of traditional guideline-based HF medical and device therapies, equally effective in patients with and without diabetes, a new class of glucose-lowering agents acting through the sodium-glucose cotransporter 2 (SGLT2) inhibition showed impressive results in reducing HF outcomes in individuals with diabetes and represents an active area of investigation. CONCLUSIONS: Diabetes and HF are strictly linked in a bidirectional and deadly vicious circle difficult to break. Therefore, preventive strategies and a timely diagnosis are crucial to improve outcomes in such patients. SGLT2 inhibitors represent a major breakthrough with remarkably consistent findings. However, it is still not clear whether their benefits may be definitely extended to patients with HF with preserved ejection fraction, to those without diabetes and in the acute setting.
引用
- Cavallari I, Maddaloni E, Pieralice S, et al. The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. J Clin Endocrinol Metab. 2020. PMID: 32615596. doi:10.1210/clinem/dgaa427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。